

**K181329 EliA B2-Glycoprotein I IgA Immunoassay, EliA
Cardiolipin IgA Immunoassay**Jun 25, 2018
38 days to decisionK181329 · Product code: **MSV** · Immunology
Source: <https://www.510kdatabase.net/k181329/>**SUBMISSION DETAILS**

Decision	Substantially Equivalent (Cleared)
Submission type	Traditional
Device classification	System,test,antibodies,b2 - Glycoprotein I (b2 - Gpi) (MSV)
Date received	May 18, 2018
Decision date	Jun 25, 2018
Days to decision	38 days
Third-party review	No
Summary / Statement	Summary

APPLICANT

Company	Phadia AB
Location	Uppsala, SE
Contact	Carina Magnusson
Website	http://www.phadia.com
510(k) history	32 submissions · 32 cleared · 2007-2022

Phadia AB is a medical products company headquartered in Uppsala, Sweden. The company develops, manufactures, and markets blood test systems for clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases. Phadia AB received FDA 510(k) clearances from total submissions, with no denied submissions on record. The company's regulatory focus is entirely on Immunology devices. Clearances span from 2007 to 2022, establishing a consistent track record in immunoassay and allergen testing technologies. The company's cleared devices include immunoassay systems for...

510k Database - www.510kdatabase.netDevice record: <https://www.510kdatabase.net/k181329/> Data sourced from FDA 510(k) public records (accessdata.fda.gov).510k Database is an independent platform not affiliated with the U.S. Food and Drug Administration. Always verify at accessdata.fda.gov. - Generated May 30, 2026